Infants born during COVID-19 pandemic experience increased susceptibility to airway hyperresponsiveness.

Publication date: Oct 16, 2024

Asthma, allergic rhinitis, atopic dermatitis, and food allergy are type 2 inflammation diseases. Since the 1960s, the prevalence of those diseases has steadily increased, presumably due to the “Hygiene hypothesis” which suggests that early exposure of infants to pathogens, siblings, and environmental dust, has a protective effect against the development of allergic diseases. The COVID-19 pandemic increased environmental hygiene due to lockdowns, masks, and social distancing. To compare the prevalence of allergic diseases among children born before and during the pandemic. The Cow’s Milk Early Exposure Trial prospectively followed newborns until 12-months of age using monthly survey and examined milk allergy development. Some were born before the first COVID-19 lockdown in Israel (April 2018-March 2020), and some were born during the pandemic (March 2020-May 2021). The monthly surveys included questions regarding atopic comorbidities. A total of 1,989 infants completed 12-months of follow-up. Among them, 1,086(54. 5%) were diagnosed with at least one atopic disease. Among 235 infants born after the last lockdown, 162 were diagnosed with airway hyperresponsiveness (AHR)(68. 9%), significantly more than in any other group. No other significant differences were found between the study groups. There was no significant difference in the development of atopic comorbidities between infants born before and during the pandemic. Significantly more infants who were born after restrictions were eased were diagnosed AHR. A longer follow-up period is needed to obtain a better understanding of the influence of the COVID-19 restrictions on the development of atopic comorbidities. NIH Clinical Trials Registry: NCT02785679.

Open Access PDF

Concepts Keywords
Asthma airway hyper responsiveness
Milk allergy
Siblings atopic comorbidities
COVID-19
hygiene hypothesis

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease IDO susceptibility
disease MESH airway hyperresponsiveness
disease MESH Asthma
pathway KEGG Asthma
disease MESH allergic rhinitis
disease MESH atopic dermatitis
disease MESH food allergy
disease MESH inflammation
disease MESH milk allergy
drug DRUGBANK Tropicamide
drug DRUGBANK Coenzyme M
disease MESH Allergy
pathway REACTOME Reproduction
disease IDO cell
drug DRUGBANK Isoxaflutole
disease MESH infectious diseases
disease MESH influenza
disease MESH infections
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO history
disease MESH morbidities
drug DRUGBANK Aspartame
disease MESH Emergency

Original Article

(Visited 1 times, 1 visits today)